Constitutive and inducible nuclear factor-κB in immortalized normal human bronchial epithelial and non-small cell lung cancer cell lines

Cancer Letters

Volumn 255, Issue 1, 2007, Pages 85-94

  Baby, Johnson ^a   Pickering, Brian F ^a   Vashisht Gopal, Y N ^a   Van Dyke, Michael W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

EMSA; Human bronchial epithelial cells; Non small cell lung carcinoma; Nuclear factor B; TNF

Indexed keywords

COMPLEMENTARY DNA; CYCLIN D1; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; RNA; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ARTICLE; BRONCHUS MUCOSA; CANCER CELL CULTURE; CELL IMMORTALIZATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA BINDING; HUMAN; HUMAN CELL; IMMUNE SYSTEM; INFLAMMATION; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

BRONCHI; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL NUCLEUS; CYTOPLASM; DNA; EPITHELIAL CELLS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NF-KAPPA B; TIME FACTORS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34547686047     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.03.024     Document Type: Article

References (41)

1. Rayet B., and Gélinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18 (1999) 6938-6947
2. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-κB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2 (2002) 301-310
3. Pahl H.L. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18 (1999) 6853-6866
4. Perkins N.D., and Gilmore T.D. Good cop, bad cop: the different faces of NF-κB. Cell Death Differ. 13 (2006) 759-772
5. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J. Clin. Invest. 107 (2001) 3-6
6. Aggarwal B.B. Nuclear factor-κB: the enemy within. Cancer Cell 6 (2004) 203-208
7. Perkins N.D. NF-κB: tumor promoter or suppressor?. Trends Cell Biol. 14 (2004) 64-69
8. Karin M., Yamamoto Y., and Wang Q.M. The IKK NF-κB system: a treasure trove for drug development. Nat. Rev. Drug Discov. 3 (2004) 17-26
9. Kim H.J., Hawke N., and Baldwin A.S. NF-κB and IKK as therapeutic targets in cancer. Cell Death Differ. 13 (2006) 738-747
10. Mukhopadhyay T., Roth J.A., and Maxwell S.A. Altered expression of the p50 subunit of the NF-κB transcription factor complex in non-small cell lung carcinoma. Oncogene 11 (1995) 999-1003
11. Denlinger C.E., Rundall B.K., and Jones D.R. Modulation of antiapoptotic cell signaling pathways in non-small cell lung cancer: the role of NF-κB. J. Thorac. Cardiovasc. Surg. 16 (2004) 28-39
12. Zhang Z., Ma J., Li N., Sun N., and Wang C. Expression of nuclear factor-κB and its clinical significance in nonsmall-cell lung cancer. Ann. Thorac. Surg. 82 (2006) 243-248
13. Batra R.K., Guttridge D.C., Brenner D.A., Dubinett S.M., Baldwin A.S., and Boucher R.C. IκBα gene transfer is cytotoxic to squamous-cell lung cancer cells and sensitizes them to tumor necrosis factor-α-mediated cell death. Am. J. Respir. Cell. Mol. Biol. 21 (1999) 238-245
14. Jones D.R., Broad M., Madrid L.V., Baldwin A.S., and Mayo M.W. Inhibition of NF-κB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis. Ann. Thorac. Surg. 70 (2000) 930-937
15. Kim J.Y., Lee S., Hwangbo B., Lee C.T., Kim Y.W., Han S.K., Shim Y.S., and Yoo C.G. NF-κB activation is related to the resistance of lung cancer cells to TNF-α-induced apoptosis. Biochem. Biophys. Res. Commun. 273 (2000) 140-146
16. Milligan S.A., and Nopajaroonsri C. Inhibition of NF-κB with proteosome inhibitors enhances apoptosis in human lung adenocarcinoma cells in vitro. Anticancer Res. 21 (2001) 39-44
17. Bandala E., Espinosa M., Maldonado V., and Meléndez-Zajgla J. Inhibitor of apoptosis-1 (IAP-1) expression and apoptosis in non-small-cell lung cancer cells exposed to gemcitabine. Biochem. Pharmacol. 62 (2001) 13-19
18. Oyaizu H., Adachi Y., Okumura T., Okigaki M., Oyaizu N., Taketani S., Ikebukuro K., Fukuhara S., and Ikehara S. Proteosome inhibitor 1 enhances paclitaxel-induced apoptosis in human lung adenocarcinoma cell line. Oncol. Rep. 8 (2001) 825-829
19. Sanlioglu S., Luleci G., and Thomas K.W. Simultaneous inhibition of Rac1 and IKK pathways sensitizes lung cancer cells to TNFα-mediated apoptosis. Cancer Gene Ther. 8 (2001) 897-905
20. Berman K.S., Verma U.N., Harburg G., Minna J.D., Cobb M.H., and Gaynor R.B. Sulindac enhances tumor necrosis factor-α-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-κB. Clin. Cancer Res. 8 (2002) 354-360
21. Lee K.Y., Park J.S., Jee Y.K., and Rosen G.D. Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-κB activation. Exp. Mol. Med. 34 (2002) 462-468
22. Lee C.T., Seol J.Y., Lee S.Y., Park K.H., Han S.J., Yoo C.G., Han S.K., Shim Y.S., and Kim Y.W. The effect of adenovirus-IκBα transduction on the chemosensitivity of lung cancer cell line with resistance to cis-diamminedichloroplatinum(II) (cisplatin) and doxorubicin(adriamycin). Lung Cancer 41 (2003) 199-206
23. Osaki S., Nakanishi Y., Takayama K., Pei X.H., Ueno H., and Hara N. Transfer of IκBα gene increases the sensitivity of paclitaxel mediated with caspase 3 activation in human lung cancer cell. J. Exp. Clin. Cancer Res. 22 (2003) 69-75
24. Kim Y.A., Lee W.H., Choi T.H., Rhee S.H., Park K.Y., and Choi Y.H. Involvement of p21WAF1/CIP1, pRB, Bax and NF-κB in induction of growth arrest and apoptosis by resveratrol in human lung carcinoma A549 cells. Int. J. Oncol. 23 (2003) 1143-1149
25. Rundall B.K., Denlinger C.E., and Jones D.R. Combined histone deacetylase and NF-κB inhibition sensitizes non-small cell lung cancer to cell death. Surgery 136 (2004) 416-425
26. Denlinger C.E., Rundall B.K., Keller M.D., and Jones D.R. Proteasome inhibition sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis. Ann. Thorac. Surg. 78 (2004) 1207-1214
27. Rundall B.K., Denlinger C.E., and Jones D.R. Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer. Surgery 138 (2005) 360-367
28. Grimes K.R., Daosukho C., Zhao Y., Meigooni A., and St. Clair W. Proteasome inhibition improves fractionated radiation treatment against non-small cell lung cancer: an antioxidant connection. Int. J. Oncol. 27 (2005) 1047-1052
29. Liao H.F., Kuo C.D., Yang Y.C., Lin C.P., Tai H.C., Chen Y.Y., and Chen Y.J. Resveratrol enhances radiosensitivity of human non-small cell lung cancer NCI-H838 cells accompanied by inhibition of nuclear factor-kappa B activation. J. Radiat. Res. 46 (2005) 387-393
30. Mijatovic T., Op De Beeck A., Van Quaquebeke E., Dewelle J., Darro F., de Launoit Y., and Kiss R. The cardenolide UNBS1450 is able to deactivate nuclear factor κB-mediated cytoprotective effects in human non-small cell lung cancer cells. Mol. Cancer Ther. 5 (2006) 391-399
31. Imre G., Gekeler V., Leja A., Beckers T., and Boehm M. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-κB by tumor necrosis factor-α receptor-1 down-regulation. Cancer Res. 66 (2006) 5409-5418
32. Chaturvedi M.M., Mukhopadhyay A., and Aggarwal B.B. Assay for redox-sensitive transcription factor. Methods Enzymol. 319 (2000) 585-602
33. Chiao P.J., Na R., Niu J., Sclabas G.M., Dong Q., and Curley S.A. Role of Rel/NF-κB transcription factors in apoptosis of human hepatocellular carcinoma cells. Cancer 95 (2002) 1696-1705
34. Takada Y., Fang X., Jamaluddin M.S., Boyd D.D., and Aggarwal B.B. Genetic deletion of glycogen synthase kinase-3β abrogates activation of IκBα kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J. Biol. Chem. 279 (2004) 39541-39554
35. Reddel R.R., Ke Y., Gerwin B.I., McMenamin M.G., Lechner J.F., Su R.T., Brash D.E., Park J.B., Rhim J.S., and Harris C.C. Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. Cancer Res. 48 (1988) 1904-1909
36. Atsuta J., Sterbinsky S.A., Plitt J., Schwiebert L.M., Bochner B.S., and Schleimer R.P. Phenotyping and cytokine regulation of the BEAS-2B human bronchial epithelial cell: demonstration of inducible expression of the adhesion molecules VCAM-1 and ICAM-1. Am. J. Respir. Cell. Mol. Biol. 17 (1997) 571-582
37. Shishodia S., Potdar P., Gairola C.G., and Aggarwal B.B. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-κB activation through inhibition of IκBα kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9, and cyclin D1. Carcinogenesis 24 (2003) 269-1279
38. Emmerich F., Meiser M., Hummel M., Demel G., Foss H.D., Jundt F., Mathas S., Krappmann D., Scheidereit C., Stein H., and Dörken B. Overexpression of I kappa B alpha without inhibition of NF-κB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 94 (1999) 3129-3134
39. Tang X., Liu D., Shishodia S., Ozburn N., Behrens C., Lee J.J., Hong W.K., Aggarwal B.B., and Wistuba I.I. Nuclear factor-kB (NF-kB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer 107 (2006) 2637-2646
40. Wright J.G., and Christman J.W. The role of nuclear factor kappa B in the pathogenesis of pulmonary diseases: implications for therapy. Am. J. Respir. Med. 2 (2003) 211-219
41. Park G.Y., and Christman J.W. Nuclear factor kappa B is a promising therapeutic target in inflammatory lung disease. Curr. Drug Targets 7 (2006) 661-668